Zhengye Biotechnology Holding Limited Financials
This page shows Zhengye Biotechnology Holding Limited (ZYBT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Zhengye Biotechnology Holding Limited has an operating margin of 8.8%, meaning the company retains $9 of operating profit per $100 of revenue. This results in a moderate score of 42/100, indicating healthy but not exceptional operating efficiency.
Zhengye Biotechnology Holding Limited carries a low D/E ratio of 0.02, meaning only $0.02 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Zhengye Biotechnology Holding Limited's current ratio of 1.31 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 21/100, which could limit financial flexibility.
Zhengye Biotechnology Holding Limited has a free cash flow margin of 14.7%, earning a moderate score of 62/100. The company generates positive cash flow after capital investments, but with room for improvement.
Zhengye Biotechnology Holding Limited generates a 4.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 20/100.
Zhengye Biotechnology Holding Limited scores 2.10, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($44.3M) relative to total liabilities ($19.3M). This signals moderate financial risk that warrants monitoring.
For every $1 of reported earnings, Zhengye Biotechnology Holding Limited generates $3.63 in operating cash flow ($5.6M OCF vs $1.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Zhengye Biotechnology Holding Limited earns $4.1 in operating income for every $1 of interest expense ($2.3M vs $554K). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Zhengye Biotechnology Holding Limited generated $25.5M in revenue in fiscal year 2024.
Zhengye Biotechnology Holding Limited's EBITDA was $5.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
Zhengye Biotechnology Holding Limited reported $1.6M in net income in fiscal year 2024.
Zhengye Biotechnology Holding Limited earned $0.03 per diluted share (EPS) in fiscal year 2024.
Cash & Balance Sheet
Zhengye Biotechnology Holding Limited generated $3.8M in free cash flow in fiscal year 2024, representing cash available after capex.
Zhengye Biotechnology Holding Limited held $2.5M in cash against $658K in long-term debt as of fiscal year 2024.
Zhengye Biotechnology Holding Limited had 46M shares outstanding in fiscal year 2024.
Margins & Returns
Zhengye Biotechnology Holding Limited's gross margin was 49.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs.
Zhengye Biotechnology Holding Limited's operating margin was 8.8% in fiscal year 2024, reflecting core business profitability.
Zhengye Biotechnology Holding Limited's net profit margin was 6.1% in fiscal year 2024, showing the share of revenue converted to profit.
Zhengye Biotechnology Holding Limited's ROE was 4.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Zhengye Biotechnology Holding Limited invested $1.8M in research and development in fiscal year 2024.
Zhengye Biotechnology Holding Limited invested $1.9M in capex in fiscal year 2024, funding long-term assets and infrastructure.
ZYBT Income Statement
| Metric | Q4'24 |
|---|---|
| Revenue | N/A |
| Cost of Revenue | N/A |
| Gross Profit | N/A |
| R&D Expenses | N/A |
| SG&A Expenses | N/A |
| Operating Income | N/A |
| Interest Expense | N/A |
| Income Tax | N/A |
| Net Income | N/A |
| EPS (Diluted) | N/A |
ZYBT Balance Sheet
| Metric | Q4'24 |
|---|---|
| Total Assets | $67.6M |
| Current Assets | $24.3M |
| Cash & Equivalents | $2.5M |
| Inventory | $8.0M |
| Accounts Receivable | $8.2M |
| Goodwill | N/A |
| Total Liabilities | $19.3M |
| Current Liabilities | $18.6M |
| Long-Term Debt | $658K |
| Total Equity | $38.9M |
| Retained Earnings | $6.6M |
ZYBT Cash Flow Statement
| Metric | Q4'24 |
|---|---|
| Operating Cash Flow | N/A |
| Capital Expenditures | N/A |
| Free Cash Flow | N/A |
| Investing Cash Flow | N/A |
| Financing Cash Flow | N/A |
| Dividends Paid | N/A |
| Share Buybacks | N/A |
ZYBT Financial Ratios
| Metric | Q4'24 |
|---|---|
| Gross Margin | N/A |
| Operating Margin | N/A |
| Net Margin | N/A |
| Return on Equity | N/A |
| Return on Assets | N/A |
| Current Ratio | 1.31 |
| Debt-to-Equity | 0.02 |
| FCF Margin | N/A |
Similar Companies
Frequently Asked Questions
What is Zhengye Biotechnology Holding Limited's annual revenue?
Zhengye Biotechnology Holding Limited (ZYBT) reported $25.5M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Zhengye Biotechnology Holding Limited profitable?
Yes, Zhengye Biotechnology Holding Limited (ZYBT) reported a net income of $1.6M in fiscal year 2024, with a net profit margin of 6.1%.
What is Zhengye Biotechnology Holding Limited's EBITDA?
Zhengye Biotechnology Holding Limited (ZYBT) had EBITDA of $5.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Zhengye Biotechnology Holding Limited have?
As of fiscal year 2024, Zhengye Biotechnology Holding Limited (ZYBT) had $2.5M in cash and equivalents against $658K in long-term debt.
What is Zhengye Biotechnology Holding Limited's gross margin?
Zhengye Biotechnology Holding Limited (ZYBT) had a gross margin of 49.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Zhengye Biotechnology Holding Limited's operating margin?
Zhengye Biotechnology Holding Limited (ZYBT) had an operating margin of 8.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Zhengye Biotechnology Holding Limited's net profit margin?
Zhengye Biotechnology Holding Limited (ZYBT) had a net profit margin of 6.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Zhengye Biotechnology Holding Limited's return on equity (ROE)?
Zhengye Biotechnology Holding Limited (ZYBT) has a return on equity of 4.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Zhengye Biotechnology Holding Limited's free cash flow?
Zhengye Biotechnology Holding Limited (ZYBT) generated $3.8M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Zhengye Biotechnology Holding Limited's operating cash flow?
Zhengye Biotechnology Holding Limited (ZYBT) generated $5.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Zhengye Biotechnology Holding Limited's total assets?
Zhengye Biotechnology Holding Limited (ZYBT) had $67.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Zhengye Biotechnology Holding Limited's capital expenditures?
Zhengye Biotechnology Holding Limited (ZYBT) invested $1.9M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Zhengye Biotechnology Holding Limited spend on research and development?
Zhengye Biotechnology Holding Limited (ZYBT) invested $1.8M in research and development during fiscal year 2024.
What is Zhengye Biotechnology Holding Limited's current ratio?
Zhengye Biotechnology Holding Limited (ZYBT) had a current ratio of 1.31 as of fiscal year 2024, which is considered adequate.
What is Zhengye Biotechnology Holding Limited's debt-to-equity ratio?
Zhengye Biotechnology Holding Limited (ZYBT) had a debt-to-equity ratio of 0.02 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Zhengye Biotechnology Holding Limited's return on assets (ROA)?
Zhengye Biotechnology Holding Limited (ZYBT) had a return on assets of 2.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Zhengye Biotechnology Holding Limited's Altman Z-Score?
Zhengye Biotechnology Holding Limited (ZYBT) has an Altman Z-Score of 2.10, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Are Zhengye Biotechnology Holding Limited's earnings high quality?
Zhengye Biotechnology Holding Limited (ZYBT) has an earnings quality ratio of 3.63x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Zhengye Biotechnology Holding Limited cover its interest payments?
Zhengye Biotechnology Holding Limited (ZYBT) has an interest coverage ratio of 4.1x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Zhengye Biotechnology Holding Limited?
Zhengye Biotechnology Holding Limited (ZYBT) scores 49 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.